Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "labs"

432 News Found

Dr. Lal PathLabs selects Kyndryl for cloud services management
Digitisation | March 14, 2023

Dr. Lal PathLabs selects Kyndryl for cloud services management

Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces


Redcliffe Labs launches BD MAX MDR TB test for MDR-TB in a Single test
Clinical Trials | February 21, 2023

Redcliffe Labs launches BD MAX MDR TB test for MDR-TB in a Single test

Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test


Briefs: Biocon, Laurus Labs and Smruthi Organics
Drug Approval | February 13, 2023

Briefs: Biocon, Laurus Labs and Smruthi Organics

Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.


Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
News | January 29, 2023

Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr

The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022


Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
News | December 21, 2022

Indira IVF forays into diagnostic business with ‘Indira Pathlabs’

Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients


Laurus Labs takes stake in Ethan Energy India
News | November 25, 2022

Laurus Labs takes stake in Ethan Energy India

This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant


Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr
News | November 19, 2022

Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr

The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022


USFDA issues Form 483 for Parawada unit of Laurus Labs
Drug Approval | October 30, 2022

USFDA issues Form 483 for Parawada unit of Laurus Labs

The observation is procedural in nature and the company will address the observation within stipulated timelines.


Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
News | October 28, 2022

Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23

The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022


Laurus Labs planning Rs. 2,000 Cr Capex
News | October 27, 2022

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions